“We continue to expect cancer diagnostics growth in the second half of the year to be higher than the first half of the year to be higher than the first half supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption.”

In context

“ct strong and stable demand for testing. We view this as a positive indication of the durable underlying demand for healthcare, not just in the US, but globally. This durable demand was evident in our core laboratory results this quarter where US business grew 7.5%, and we continue our track record of strong performance across Latin America. In rapid and molecular diagnostics, sales declined 8% driven by the anticipated decrease in respiratory testing, as a result of a weaker than normal season that concluded during the second quarter. In cancer diagnostics, sales growth of 13% was driven by mid teens growth of Cologuard. Which is benefiting from a growing base of both new and repeat Cologuard users as well as contributions to growth from our precision oncology and international business. We continue to expect cancer diagnostics growth in the second half of the year to be higher than the first half of the year to be higher than the first half supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption. In May, the American Cancer Society updated its colorectal cancer screening guidelines reaffirming Cologuard and Cologuard Plus as preferred screening options. This designation reflects Cologuard's market leading accuracy and superior ability to detect cancer at earlier stages compared to other available tests. Moving to nutrition. Where sales finished slightly ahead of our expectations for the second consecutive quarter, Sales increased sequentially by $125 million. Driven by improving performance in both pediatric and adult nutrition. In pediatric nutrition, our adult in pediatric nutrition, our international business was the first of our nutrition businesses to transition back to delivering positive growth delivering growth of 6.5% in the quarter. In US pediatric, we exited the quarter”